Mifeprex Approval.pdf

The US Food and Drug Administration (FDA) approved Mifeprex in September 2000 for terminating early-term pregnancy under Subpart H regulations, which restrict distribution to ensure safe use. The approval process involved three review cycles, with FDA evaluating the sponsor's new drug application and imposing distribution restrictions. The agency required the sponsor to conduct postmarketing studies, restricted distribution to qualified physicians, and mandated patient attestation to understanding potential complications.

The approval process for Mifeprex was consistent with that of other Subpart H restricted drugs, with common elements including evaluation of potential limitations in clinical data, imposition of distribution restrictions, and requirements for postmarketing studies. FDA's postmarket oversight of Mifeprex has also been consistent with its oversight of other Subpart H restricted drugs, including review of data, inspections, and evaluation of adverse event reports.

Key findings include:

FDA approved Mifeprex after evaluating clinical evidence supporting its safety and efficacy.
The approval process for Mifeprex was generally consistent with that of other Subpart H restricted drugs.
FDA's postmarket oversight of Mifeprex has been consistent with its oversight of other Subpart H restricted drugs.
FDA investigated deaths of six US women who developed severe infections after taking Mifeprex and concluded that the evidence did not establish a causal relationship between the drug and the infections.

The report provides detailed information on the approval and oversight process for Mifeprex, including timelines, distribution restrictions, and postmarketing requirements. It also compares the approval and oversight process for Mifeprex with that of other Subpart H restricted drugs.